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Abstract
Background: Glaucoma is a chronic disease characterized by irreversible optic nerve damage and visual field loss
that leads to visual impairment and blindness; ultimately limiting personal independence and compromising overall
quality of life of affected individuals. There is paucity of information on how glaucoma affects the quality of life of
patients in low and middle-income countries where resources for both diagnosis and treatment of such conditions
are limited. In this study we investigate the impact of glaucoma on quality of life in Ethiopian patients.
Methods: The quality of life of 307 glaucoma patients and 76 normal controls that were frequency matched to the
age and sex profiles of the cases was assessed using Amharic version of Glaucoma Quality of Life −15 questionnaire.
Linear regression models and the t-test were employed to compare significant differences in GQL-15 scores and to
generate mean and mean differences between cases and controls respectively.
Results: The mean GQL-15 score in the glaucoma cases was substantially higher (indicating poorer quality of life) than
the controls [cases 46.3 (95% CI, 28.8–63.8) and controls 18.6 (95% CI, 15.2–22.0), p < 0.0001]. Cases with normal visual
acuity and mild glaucoma had significantly higher scores than the controls. Poorer quality of life was associated with
age≥ 71 years old 51.1 (95%CI, 26.2–75.9), rural residence 55.7 (95%CI, 49.9–61.5), monthly income of <400 Birr (53.1;
95%CI, 50.5–55.6), diagnosis time 1–5 years (49.6; 95%CI, 41.2–57.9), severe visual impairment (70.5; 95%CI, 58.1–82.8),
and advanced glaucoma (50.9; 95%CI, 43.6–58.3).
Conclusion: These glaucoma patients, including those with normal visual acuity and early disease, had poorer quality
of life compared to normal controls. Older age, rural residence, low income and more advanced disease were significantly
associated with poorer quality of life. There is a need to increase awareness of the impact of glaucoma among clinicians,
patients and their families, for a better understanding of the impact this disease has on a person’s life.
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Background
The World Health Organization (WHO) defines Quality
of Life (QOL) as an “individuals’ perceptions of their
position in life in the context of the culture and value
systems in which they live and in relation to their goals,
expectations, standards and concerns” [1]. QOL is a broad
and complex concept. It is affected by a person’s physical
health, psychological state and level of independence,
social relationships and environment. Vision Related
Quality of Life (VRQOL) specifically focuses on a person’s
satisfaction with their visual function and how their vision
impacts on their daily life [2].
A group of eye diseases that can particularly comprom-
ise VRQOL are the glaucomas. The glaucomas are charac-
terised by damage to the optic nerve with corresponding
visual field loss. Sight loss due to glaucoma is irreversible.
Typically, patients initially loose the mid-periphery of their
visual field, while central vision tends to be involved later.
The patients become aware of a functional defect when
visual field loss impinges upon or involves central vision
[3, 4]. Patients with advanced glaucoma may experience
difficulty in recognizing faces, navigating, reading, watch-
ing television, noticing objects in their peripheral vision,
and adapting to different levels of lighting. Moreover, they
are also at increased risk of falls and accidents [5].
Besides the visual impairment (VI) and field loss, living
with a chronic disease like glaucoma may negatively impact
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an individual’s QOL through greater dependence on other
individuals for basic daily activities, stress/concern about the
diagnosis, the need for lifelong treatment and follow-up, and
the cost and side effects of treatment [6].
According to the WHO, glaucoma is the second leading
cause of avoidable blindness after cataract, contributing 8%
of total blindness worldwide [7]. This figure could be as high
as 15% in some low- and middle-income countries (LMIC),
particularly in Sub-Saharan Africa [8]. The Nigeria National
Blindness and Visual Impairment Survey found that
Glaucoma blindness was the second most prevalent blinding
condition after cataract [9]. In the Ethiopian National
Blindness and Low Vision Survey, which was conducted in
2005, glaucoma was found to be the fifth leading causes of
blindness in Ethiopia (contributing 5.2% to the total
blindness) [10]. The fact that the survey included individuals
with visual acuity worse than 6/18 in either eyes and the
exclusion of patients with corneal opacity from intra ocular
measurement could have resulted in underestimation of the
prevalence of glaucoma.
There is limited information on how the QOL of individ-
uals is affected by glaucoma in LMIC like Ethiopia, where
resources for both diagnosis and treatment are limited. In
this case-control study we investigate the impact glaucoma
has on the QOL of Ethiopian individuals with this disease.
Methods
Ethical considerations
This study was reviewed and approved by the Ethics Com-
mittee of the College of Medicine and Health Sciences, Uni-
versity of Gondar, Ethiopia. The nature of the study was
explained to potential participants. Individuals were enrolled
into the study if they gave informed verbal consent. No
names or identifying information were recorded on the
questionnaires. Interviews were conducted in private, and all
subjects were assured of confidentiality.
Study participants
Participants were recruited at the Ophthalmology Out-
patient Department, University of Gondar Eye Care and
Training Centre, Amhara Region, Ethiopia. In this study the
cases were consecutive individuals with a diagnosis of
glaucoma attending the department between April 24 and
May 27, 2015. We excluded individuals with glaucoma who
also had (i) high refractive errors (greater than ±5 Diopters),
(ii) visually significant cataracts (greater than Stage 2 LOCS
III classification) [11], (iii) any other visually significant
ocular pathology, (iv) a history of intraocular surgery (inci-
sional or laser) in the preceding 3 months. We also excluded
individuals with a major systemic illness or physical disabil-
ities that could affect response to GQoL-15 questionnaire.
The control participants were also recruited from patients
attending the same Ophthalmology Outpatient Department.
The controls had a visual acuity of 6/9 or better (+/−
correction) and otherwise healthy eyes. Pseuodophakic
individuals with a visual acuity of 6/9 or better were eligible.
We excluded individuals who had (i) high refractive errors
(greater than ±5 Diopters), (ii) visually significant lens opaci-
ties (greater than Stage 2 LOCS III classification), (iii) suspi-
cious optic discs, or (iv) corrected visual acuity of less than
6/9. We also excluded individuals with a major systemic
illness or physical disabilities that could affect response to
GQoL-15 questionnaire. The controls were recruited after
the case, between February 1 and May 31, 2016. We
recruited one control for every four cases; they were
frequency matched to the age and sex profile of the cases.
Clinical assessment
Cases and controls underwent a standard ophthalmic exam-
ination as part of their routine clinical care at the depart-
ment. The presenting distance visual acuity (VA), with
spectacle correction if available, was measured for each eye
separately using a tumbling-E Snellen visual acuity chart at
six metres. Pinhole test was done for those with visual acuity
6/18 or worse. If participants were unable to see this at six
metres, the testing distance was reduced to three metres. If
they failed to see any letters at three metres, vision was
assessed for “counting fingers” (CF), “Hand Movement”
(HM) or “Perception of Light” (POL). Presenting distance
visual acuity was defined by the revised WHO classification,;
patients were categorized according to the vision in the
better seeing eye [12]:
 Mild or no visual impairment: presenting distance
visual acuity equal to or better than 6/18
 Moderate visual impairment: presenting distance
visual acuity worse than 6/18 but equal to or better
than 6/60
 Severe visual impairment: presenting distance
visual acuity worse than 6/60 but equal to or better
than 3/60
 Blindness: presenting distance visual acuity worse
than 3/60
The eyes were examined by an ophthalmologist specia-
lised in glaucoma (2 years fellowship training in glaucoma).
The anterior segment was assessed using a slitlamp bio-
microscope, intraocular pressure (IOP) measured by Gold-
man tonometry, the anterior chamber angle was examined
by gonioscopy and stereoscopic optic nerve head evaluation
performed using a 90D (Volk Optical Inc.) indirect lens.
Glaucomatous Optic Neuropathy (GON) was defined
based on the scheme developed by the International
Society of Geographical and Epidemiological Ophthal-
mology [13]. Cases were diagnosed if one or more of the
following optic nerve head changes were observed in
either eye: (1) vertical cup to disc ratio (VCDR) of ≥0.7
or (2) a difference in the VCDR of ≥0.2 between the 2
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eyes or (3) the narrowest remaining vertical neuro-
retinal rim of ≤0.1 disc diameter. We did not include
visual field (VF) assessment in the diagnosis and staging
of glaucoma in this study as the test was only performed
by a minority of our patients.
The following operational definitions for the sub-types
of glaucoma were used [13]:
 Primary open angle glaucoma (POAG): optic nerve
damage meeting any of the three categories of
evidence above, in an eye which does not have
evidence of angle closure on gonioscopy, and where
there is no identifiable secondary cause.
 Pseudoexfoliative glaucoma (XFG) is open angle
glaucoma associated with characteristic
pseudoexfoliative material deposited at the pupil
margin or anterior surface of the lens; on gonioscopy
there may be with hyperpigmention of the trabecular
meshwork or exfoliative material in the angle.
 Chronic angle closure glaucoma (CACG) is optic
nerve damage meeting any of the three categories of
evidence above, in an eye which have evidence of
angle closure on gonioscopy, and where there is no
identifiable secondary cause.
The severity of glaucoma was staged using the Canadian
Ophthalmological Society evidence-based clinical practice
guidelines for the management of glaucoma in the adult
eye [14]:
 Early Glaucoma: Early glaucomatous disc features (e.g.,
VCDR 0.7) and (or) mild VF defect not within 10° of
fixation (e.g., MD better than −6 dB on HVF 24–2)
 Moderate Glaucoma: Moderate glaucomatous disc
features (e.g., VCDR 0.75–0.85) and (or) moderate
VF defect not within 10° of fixation (e.g., MD from
−6 .to −12 dB on HVF 24–2)
 Advanced Glaucoma: Advanced glaucomatous disc
features (e.g. VCDR >0.9) and (or) VF defect within 10°
of fixation (e.g., MD worse than −12 dB on HVF 24–2)
Structured interview
A structured, pre-tested questionnaire that consisted of
questions on socio-demographic characteristics, clinical
assessment of glaucoma and the Glaucoma Quality of
Life-15 (GQL-15) questionnaire was used to collect data
[15]. The questionnaire was translated into the local
language (Amharic) and then back translated into
English by expertise and 5% of the questionnaire was
pre-tested. Data were collected through face to face
interviews (most study participants were illiterate) and
medical chart review.
The GQL-15 is a user friendly 15-item questionnaire
made up of four domains of perceived visual disability: (1)
central/near vision, (2) outdoor mobility, (3) peripheral vi-
sion and (4) glare / dark adaptation [16]. There are
different numbers of question items in the four domains:
central/near vision (2 items), outdoor mobility (1 item),
peripheral vision (6 items) and glare / dark adaptation (6
items). Therefore the maximum potential score the
domains also vary. It is a well validated tool with high
internal consistency and test-retest reliability [15, 17]. The
GQL-15 has a scoring scale ranging from 1 to 5, where 1
stands for “no difficulty in performing the activity” and 5
for “severe difficulty due to visual reasons”. If patients do
not perform a specific activity for reasons other than
impaired vision, a score of 0 is given for that task. This can
yield a total score of between 0 and 75. Poorer GQL-15
and increasing difficulty with vision-related activities were
associated with higher subscale scores [17–20].
Data analysis
The coded data were checked, cleaned and entered into Epi
Info version 7 and then exported into SPSS Version 20
(SPSS, Chicago III) for analysis. Frequencies, percentage,
mean and standard deviation were used to describe study
results as required. To calculate the subscale scores for the
four domains of the GQL-15, the item level responses were
scored on a numerical interval scale ranging from 0,
indicating no difficulty, to 5, indicating severe difficulty.
The subscale score for each domain was calculated using
an average of the scores generated for the component item-
level responses. Comparisons of cases and controls were
done after adjusting variables for age and sex. Linear regres-
sion models and the t-test were employed to compare
significant differences in GQL-15 scores and to generate
mean and mean differences between cases and controls in
each GQL-15 subscale and domain, respectively. Univari-
able analysis was first conducted for each variable. Variables
that satisfied p-value <0.2 were selected for further analysis.
The strength of association was interpreted using confi-
dence interval. P-value <0.05 was accepted as statistically
significant in this study.
Results
Socio-demographic characteristics
We recruited 307 glaucoma patients (cases) and 76
controls. The socio-demographic characteristics of the
study participants are presented in Table 1. The age (p =
0.62) and sex (p = 0.87) distribution of the cases and
controls were highly comparable. The mean age of the
cases was 60.3 years (SD ± 14.0) and controls was
59.5 years (SD ±12.5). The large majority were married,
with no evidence of a difference in marital status
between groups (p = 0.06). Most were of Amhara ethni-
city. Overall, the majority of participants lived in rural
areas, however, there were proportionately more people
from rural areas among the controls (75.0%) compared
Ayele et al. BMC Ophthalmology  (2017) 17:248 Page 3 of 9
to the cases (55.4%) (p = 0.02). Educational level and
occupation types were comparable between cases and
controls. There was some evidence of a difference in
income, with the controls earning slightly more than the
cases (p = <0.0001).
Clinical characteristics
The clinical characteristics of the cases are shown in
Table 2. The majority had been diagnosed for between 1
and 5 years (194, 63.2%) and had bilateral disease (279,
90.9%). One hundred and thirteen (36.8%) had advanced
glaucoma (determined by the extent of optic nerve dam-
age) and 70 (22.8%) cases were either severely visual im-
paired or blind. The most frequent types of glaucoma
were primary open angle glaucoma (164, 53.4%) and
pseudoexfoliative glaucoma (111, 36.2%). Most of the
control groups had a visual acuity of 6/6 (42, 55.3%)
while the rest had 6/9. The main clinical diagnoses in
the control groups include early cataract (24, 31.6%),
corrected refractive errors (21, 27.6%) and pseudophakia
with good outcome (16, 21.1%).
Quality of life
The mean GQOL-15 scores of glaucoma cases and the
controls are presented in Table 3. The mean GQL-15
Table 1 Socio-demographic characteristics of study participants
Variable Cases Controls p-value*
n/307 (%) n/76 (%)
Sex 0.87
Male 201 (65.5) 49 (64.5)
Female 106 (34.5) 27 (35.5)
Age 0.62
18–30 7 (2.3) 2 (2.6)
31–40 22 (7.2) 5 (6.6)
41–50 33 (10.7) 8 (10.5)
51–60 61 (19.9) 15 (19.7)
61–70 110 (35.8) 28 (36.8)
≥ 71 74 (24.1) 18 (23.7)
Marital status 0.06
Married 216 (70.4) 62 (81.6)
Widowed 40 (13.0) 10 (13.2)
Divorced 28 (9.1) 2 (2.6)
Single 23 (7.5) 2 (2.6)
Ethnicity 0.65
Amhara 298 (97.1) 73 (96.1)
Tigre 9 (2.9) 3 (3.9)
Religion 0.16
Orthodox Christian 283 (92.2) 64 (84.2)
Muslim 19 (6.2) 12 (15.8)
Protestant 5 (1.6)
Residence 0.02
Urban 137 (44.6) 19 (25.0)
Rural 170 (55.4) 57 (75.0)
Education 0.20
None 138 (45.0) 42 (53.3)
Informal (able to read and write) 93 (30.3) 18 (23.7)
Primary school 29 (9.4) 7 (9.2)
Secondary school and above 47 (15.3) 9 (11.8)
Occupation 0.03
Government employee 56 (18.2) 15 (19.7)
Farmer 130 (42.3) 43 (56.6)
House wife 65 (21.2) 11 (14.5)
Dependent on family 56 (18.2) 7 (9.2)
Monthly Income (Ethiopian Birr) <0.0001
< 400 119 (48.5) 10 (13.2)
400–1000 110 (35.8) 42 (55.3)
> 1000 48 (15.6) 24 (31.6)
*p-values were calculated by t-test and adjusted for age and gender
Table 2 Clinical characteristics of 307 cases with glaucoma
Variable n/307 (%)
Duration of diagnosis
< 1 year 75 (24.4)
1-5 Years 194 (63.2)
≥ 6 years 38 (12.4)
Duration of treatment
< 1 year 156 (50.8)
1–5 years 130 (42.3)
≥ 6 years 21 (6.8)
Presence of other ocular disease
Yes 149 (48.5)
No 158 (51.5)
Visual Acuity (better eye)
Normal 111 (36.2)
Moderate visual impairment 126 (41.0)
Severe visual impairment 58 (18.9)
Blind 12 (3.9)
Type of glaucoma
Primary open angle glaucoma 164 (53.4)
Pseudoexfoliation glaucoma 111 (36.2)
Chronic angle closure glaucoma 32 (10.4)
Stage of glaucoma
Early 126 (41.0)
Moderate 68 (22.1)
Advanced 113 (36.8)
Laterality
Unilateral 28 (9.1)
Bilateral 279 (90.9)
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score was substantially higher (indicating poorer quality of
life) among the glaucoma cases than the controls (46.3 vs
18.6, p < 0.0001). The glaucoma cases had higher scores
than the controls for all four domains (p < 0.0001).
The relationship between GQL-15 scores and demo-
graphic characteristics among individuals with glaucoma are
presented in Table 4. A higher total GQL-15 and domain
scores (poorer QOL) were found for men, older people,
illiterate individuals, rural residents, and people with lower
monthly income. These same factors remained significant
after adjustment in a multivariable linear regression model.
The relationship between GQL-15 scores and clinical
characteristics among the glaucoma cases are presented in
Table 5. Increasing severity of glaucoma, longer duration of
glaucoma and decreasing visual acuity were all associated
with higher GQL-15 scores.
We performed a sub group analysis comparing cases with
no or only mild VI to the controls [Table 6]. The mean
GQL-15 scores for this sub-group of glaucoma cases still
had worse QOL than the controls. Similarly, we compared
the sub-group of cases with early glaucoma to the controls
[Table 7]. This sub-group of cases had worse GQL-15
scores than the controls.
Discussion
In this study, using the GQL-15 assessment tool, we
found that Ethiopian glaucoma patients had a poorer
QOL compared to unaffected controls. Moreover,
among the glaucoma cases, those with more advanced
disease and poorer visual acuity had substantially poorer
QOL scores. Onakoya et al. also demonstrated similar
findings among Nigerian patients in their two separate
reports [19, 20]. Multiple factors contributed to this
glaucoma related reduced QOL. For example people
with more advanced glaucoma will have peripheral and
central visual impairment that could have an impact on
their ability to move around, find objects, perform activ-
ities of daily living and adapting to changing lighting
levels. They may be at increased risk of falls and acci-
dents [5, 6].
The mean GQL-15 score difference between glaucoma
cases and controls was significantly higher in domains of
peripheral vision and dark adaptation and glare. This
observation is consistent with earlier studies which have
found that visual disability related to tasks associated with
dark adaptation or glare, like walking after dark, seeing at
night, adjusting to different levels of illumination and
activities demanding peripheral vision such as avoiding
tripping over and bumping into objects, seeing objects
coming from the side and judging distances, are associated
with impaired binocular visual field loss [15, 19–21].
A subgroup analysis found the mean GQL-15 scores
of glaucoma patients with visual acuity of 6/18 or better
and those with mild glaucoma were higher than the
controls. This suggests that QOL can be reduced in
glaucoma patients in this environment, even in the early
stages of the disease. Similar observations have been
made in other studies [15, 20, 22–24]. It is possible that
factors other than the early functional visual loss, such
as concern about the diagnosis and the need for lifelong
treatment may also affect the perceived quality of,
although the GQL-15 tool does not directly assess
these issues.
We also observed that glaucoma patients who were
rural residents with high illiteracy status to have poorer
QoL. Generally, rural residents of developing countries
like Ethiopia have poor access to eye care services [25].
Besides, the low literacy status might contribute to the
poor health seeking behaviour observed in people living in
rural areas that may result in the late diagnosis of the
disease with severe visual impairment. Furthermore, most
of the people from rural area had poor income to afford
for their transportation and treatment related expenses.
We used the GQL-15 questionnaire, which is well
validated with high internal consistency and test-retest
reliability and had been used in Africa glaucoma
patients. In one Nigerian study that compared the
NEIVFQ25 (25-item National Eye Institute Visual
Function Questionnaire) and the GQL-15 both appeared
reliable in the assessment of QOL. They found the
GQL-15 to be a shorter, simpler instrument, which
could be easily administered in clinical practice [19].
The main limitation of this study was that it was cross-
sectional; longitudinal study would have provided
additional information about the changes in QOL
throughout different stages of the disease.
Table 3 Distribution of the four subscales of the GQOL-15 scores in glaucoma cases and controls
Domain Cases Controls Difference P value*
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Central and Near vision 6.1 (3.5–8.7) 3.3 (2.5–4.1) 2.8 (2.5–3.1) <0.0001
Outdoor mobility 3.2 (1.8–4.6) 1.3 (0.9 1.7) 1.9 (1.7–2.1) <0.0001
Peripheral vision 19.3 (10.3–28.3) 7.2 (6.7–7.7) 12.1 (11.1–13.1) <0.0001
Dark adaptation & Glare 17.7 (11.7–23.7) 6.9 (4.7–9.1) 10.8 (10.1–11.5) <0.0001
Overall Score 46.3 (28.8–63.8) 18.6 (15.2–22.0) 27.7 (23.7–31.6) <0.0001
*p-values were calculated by t-test and adjusted for age and gender
Ayele et al. BMC Ophthalmology  (2017) 17:248 Page 5 of 9
Prevention of sight loss from glaucoma is particularly
challenging in the African context. Patients frequently
present late with advanced disease. Optometry services
are not generally well developed and usually only available
in larger urban centres. Therefore, there is relatively little
opportunistic detection of glaucoma and simple, cost
effective strategies are needed to find individuals with
glaucoma before they develop substantial loss of vision.
However, even when detected, further barriers to preven-
tion of sight loss remain. Treatment is costly in relative
terms and it is often difficult for the patient to sustain
long-term access to medication. Therefore patient educa-
tion and counselling are really important.
We found that glaucoma patients in Ethiopia, includ-
ing those with normal visual acuity and early disease,
have a poorer quality of life as compared to unaffected
Table 4 Univariable and multivariable associations of glaucoma related quality of life with demographic characteristics
Variable Domain
Central & near vision Outdoor Mobility Peripheral vision Dark adaptation and glare Overall score
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Age (years)
18–30 3.7 (1.9–5.5) 1.9) (0.9–2.9 11.6 (5.1–18.0) 12.4 (8.4–16.5) 29.6 (17.4–41.7)
31–40 2.9 (0.8–6.9) 1.8 (0.4–3.9) 11.5 (−2.2–25.5) 11.7 (3.0–20.4) 28.2 (2.1–54.3)
41–50 5.9 (2.2–9.7) 2.9 (0.8–5.0) 18.6 (5.0–32.1) 14.4 (6.0–23.0) 41.9 (16.3–67.4)
51–60 5.8 (2.1–9.4) 3.0 (0.9–5.0) 18.7 (5.4–32.0) 16.5 (8.2–24.9) 44 (18.9–68.9)
61–70 4.8 (2.9–10.2) 3.6 (1.6–5.6) 21.0 (7.9–34.1) 19.2 (11.1–27.5) 50.4 (25.7–75.0)
> 70 6.8 (3.2–10.5) 3.6 (1.6–5.7) 20.7 (7.5–33.9) 19.9 (11.7–28.3) 51.1 (26.2–75.9)
P valuea <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P valueb <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Sex
Male 7.2 (6.1–8.4) 3.8 (3.2–4.5) 24.9 (20.8–29.1) 20.8 (18.1–23.6) 56.9 (48.8–64.9)
Female 6.1 (4.0–8.4) 2.8 (2.0–4.5) 19.7 (11.9–27.7) 17.9 (12.7–23.1) 47.1 (31.7–62.4)
P valuea 0.02 0.03 0.02 0.03 0.01
P valueb – – – – 0.06
Residence
Rural 7.4 (6.5–8.2) 3.9 (3.4–4.3) 23.9 (20.9–26.9) 20.5 (18.5–22.5) 55.7 (49.9–61.5)
Urban 6.4 (4.9–7.8) 3.4 (2.5–4.1) 20.6 (15.2–25.5) 18.3 (14.8–21.7) 48.4 (38.3–58.5)
P valuea <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P valueb <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Educational status
Unable to write and read 6.7 (6.3–7.1) 3.5 (3.3–3.7) 21.0 (19.6–22.3) 18.6 (17.6–19.5) 49.8 (47.2–52.4)
Only read and write 6.8 (5.8–7.7) 3.6) (3.1–4.1 22.5 (19.0–25.9) 19.5 (17.0–21.8) 52.4 (45.7–59.0)
Primary school (1–8) 4.3 (3.0–5.6) 2.3 (1.6–3.0) 15.3 (10.6–19.8) 13.8 (10.6–17.0) 35.7 (26.9–44.5)
Secondary school (9–12) 4.8 (3.4–6.2) 2.1 (1.3–2.8) 13.5 (8.6–18.4) 17.3 (13.9–20.5) 37.7 (28.3–47.2)
Certificate and above 3.1 (1.7–4.5) 1.5 (0.7–2.5) 8.3 (3.4–13.1) 11.0 (7.0–14.3) 23.9 (14.6–33.2)
P valuea <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P valueb <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Monthly income (ETB)
< 400 6.9 (6.6–7.3) 3.7 (3.5–3.9) 22.9 (21.6–24.2) 19.5 (18.6–20.4) 53.1 (50.5–55.6)
401–1000 5.6 (4.8–6.6) 3.1 (2.6–3.6) 18.3 (15.0–21.6) 16.7 (14.4–19.0) 43.8 (37.3–50.2)
> 1000 4.3 (3.3–5.5) 1.7 (1.1–2.3) 10.8 (16.8–14.6) 14.1 (11.4–16.9) 30.9 (23.2–38.6)
P valuea <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P valueb <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
All p-values are calculated using linear regression
aP-values from univariable linear regression analysis
bP-values from multivariable linear regression analysis
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Table 5 Univariable and multivariable associations of glaucoma related quality of life with clinical characteristics
Variable Domain
Central and near vision Outdoor Mobility Peripheral vision Dark adaptation and glare Overall score
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Duration of diagnosis
< 1 year 4.9 (4.3–5.4) 2.7 (2.3–3.0) 16.2 (14.2–18.2) 14.7 (13.4–16.0) 38.5 (34.6–42.3)
1–5 years 6.5 (5.2–7.7) 3.5 (2.7–4.1) 20.7 (16.3–25.1) 18.9 (16.1–21.7) 49.6 (41.2–57.9)
> 5 years 6.5 (4.9–8.0) 3.1 (2.1–3.9) 16.3 (12.9–23.8) 17.0 (13.5–20.6) 35.0 (34.4–55.4)
P valueac <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P valueb <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Duration of treatment
< 1 year 6.0 (5.6–6.4) 3.0 (2.8–3.2) 18.7 (17.2–20.1) 16.8 (15.9–17.7) 44.5 (41.8–47.3)
1–5 years 6.1 (5.1–7.1) 3.4 (2.9–3.9) 20.1 (16.5–23.6) 18.1 (16.5–21.1) 48.5 (41.6–55.3)
> 5 years 6.5 (5.0–8.1) 3.0 (2.1–3.8) 19.9 (14.3–25.3) 16.6 (13.1–20.3) 46.1 (35.3–56.8)
P valuead <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P valueb <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Visual acuity
Normal 4.8 (4.4–5.2) 2.5 (2.3–2.7) 15.2 (13.6–16.7) 14.8 (13.8–15.9) 37.3 (34.3–40.2)
Moderate VI 6.3 (5.3–7.3) 3.4 (2.9–4.0) 20.5 (17.0–24.3) 18.7 (16.1–21.2) 49.1 (42.1–56.0)
Severe VI 7.4 (6.3–8.6) 3.7 (3.0–4.3) 21.7 (17.6–25.9) 19.6 (16.8–22.5) 52.5 (44.5–60.4)
Blind 9.7 (7.9–11.4) 4.9 (3.8–5.9) 32.0 (25.5–38.4) 23.9 (19.6–28.3) 70.5 (58.1–82.8)
P valuea <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P valueb <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Glaucoma stage
Early 5.3 (4.9–5.7) 2.8 (2.6–3.1) 16.9 (15.3–18.4) 16.2 (15.1–17.2) 41.2 (38.2–44.2)
Moderate 6.6 (5.4–7.8) 3.2 (2.6–3.9) 19.9 (15.7–24.0) 18.4 (15.6–21.2) 48.2 (40.1–56.2)
Advanced 6.7 (5.6–7.7) 3.5 (2.9–4.2) 21.8 (17.9–25.5) 19.0 (16.4–21.4) 50.9 (43.6–58.3)
P valuea <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P valueb <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
VI visual impairment
aP-values from univariable linear regression analysis
bP-values from multivariable linear regression analysis
cP-value results are for duration of diagnosis 1–5 years
dP-value results are for duration of treatment 1–5 years
Table 6 Comparison of mean GQL-15 scores of glaucoma cases and controls with a presenting visual acuity of 6/18 or better in the
better eye
Domain Cases with normal visual acuity (n = 111) Controls (n = 76) Mean difference P value*
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Central and Near vision domain 4.8 (4.4–5.2) 3.3 (2.5–4.1) 1.5 (0.9–2.1) <0.0001
Outdoor mobility domain 2.5 (2.3–2.7) 1.3 (0.9–1.7) 1.2 (1.0–2.0) <0.0001
Peripheral vision domain 15.2 (13.6–16.7) 7.2 (6.7–7.7) 8.3 (6.2–9.7) <0.0001
Dark adaptation and Glare domain 14.8 (13.8–15.9) 6.9 (4.7–9.1) 7.9 (6.6–9.2) <0.0001
Overall Score 37.3 (34.3–40.2) 18.6 (15.2–22.0) 18.7 (15.1–22.1) <0.0001
*p-values were calculated by T-test and adjusted for age and gender
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controls. Older age, rural residence, low income and
worsening severity of the disease were significantly
associated with poorer quality of life. This is important
information to share with glaucoma patients. There is a
need to increase awareness of the impact of glaucoma
among clinicians, patients and their families, for a better
understanding of the impact this disease has on a
person’s life.
Conclusions
It should be emphasized that the main goal in the
management of glaucoma should not only be to preserve
visual function by slowing or halting progression of the
disease but should also include the maintenance or
enhancement of QOL. Patients should be linked to
vision rehabilitation and psychosocial support services.
Demand based visual rehabilitation like hand held
magnifiers for near work and hand held telescopes for
distance magnification will enable patients to function
independently and be a more integral part of society
[26]. Patients with glare concerns can be provided with
glare filters. Patients with advanced visual loss can be
linked to blindness agencies for orientation and mobility
training using cane, which is a valuable means of
enabling patients to travel independently [27]. Appropri-
ate psychosocial support for patients will also help them
fight the anxiety brought by the fear of progressive
losing of the remaining vision.
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